

4. (Amended) An immunomodulator according to claim 1, wherein the T-cell binding site of the antigen-presenting cell (APC) targeting molecule has been deleted.

5. (Amended) An immunomodulator according to claim 1, wherein the antigen-presenting cell (APC) targeting molecule is derived from *Staphylococcus aureus* and/or *Streptococcus pyogenes*.

8. (Amended) An immunomodulator according to claim 6, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A R181Q.

9. (Amended) An immunomodulator according to claim 6, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A.C27S.N79C.R181Q.

10. (Amended) An immunomodulator according to claim 1, wherein the antigen-presenting cell (APC) targeting molecule is coupled reversibly to an immunomodulatory antigen.

11. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is a protein, a polypeptide and/or a peptide.

12. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is a nucleic acid.

13. (Amended) An immunomodulator according to claim 1, wherein the immunomodulatory antigen is non-immunogenic when not coupled to the antigen-presenting cell (APC) targeting molecule.

14. (Amended) An immunomodulator according to claim 4, wherein the antigen-presenting cell (APC) targeting molecule is SPEC (-20-90).

15. (Amended) Pharmaceutical composition comprising an immunomodulator according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, excipient and/or solvent.

16. (Amended) Vaccine comprising an immunomodulator according to claim 1.

A3
Cancel
17. (Amended) Method of therapeutic or prophylactic treatment of a disorder which requires the induction or stimulation of the immune system, comprising the administration to a subject requiring such treatment of an immunomodulator according to claim 1.

A4
23. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is SPE-C Y15A R181Q.

24. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is designated SPEC-Y15A.C27S.N79C.R181Q.

25. (Amended) A method according to claim 21, wherein the antigen-presenting cell (APC) targeting molecule is SPEC (-20-90).

A5
30. (Amended) A method according to claim 26, wherein the antigen-presenting cell (APC) targeting molecule is derived from *Staphylococcus aureus* and/or *Streptococcus pyogenes*.

36. (Amended) A method according to claim 26, wherein the antigen-presenting- cell (APC) targeting molecule is coupled reversibly to said compound.

A6
37. (Amended) A method according to claim 26, wherein the compound is selected from the group consisting of a protein, a polypeptide and/or a peptide, a carbohydrate or a nucleic acid.

Applicant : John David [REDACTED] et al
Serial No. :
Filed : December 3, 2001
Page : 4

Attorney's Do [REDACTED] No.: 12669-002001 / 30072UPS00

*Al
could*

38. (Amended) A method according to claim 26, wherein the compound is non-immunogenic when not coupled to the antigen-presenting cell (APC) targeting molecule. ~~14~~

114
113
112
111
110
109
108
107
106
105
104
103
102
101
100
99
98
97
96
95
94
93
92
91
90
89
88
87
86
85
84
83
82
81
80
79
78
77
76
75
74
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1